Synthesis of 2'-deoxyzebularine (dZ), its phosphoramidite and
oligonucleotides containing dZ and dZ Me .
s
Reagents from commercial suppliers were used without further purification. Pyridine, Et3N and CH2Cl2 were freshly distilled from CaH2. Hoffer's chlorosugar 1 was prepared as described. 1 1 H (400.1 or 500.1 MHz), 13 C (100.6 or 125.8 MHz) and 31 P (202.5 MHz) NMR spectra were obtained with Bruker Avance 400 or Avance 500 MHz spectrometers and referenced to residual solvent signals (CDCl3: 7.26 ppm for 1 H and 77.16 ppm for 13 C, d6-DMSO: 2.50 ppm for 1 H and 39.52 ppm for 13 C according to reference 2 or 85% aq. H3PO4 external standard (0.0 ppm for 31 P). 1 H NMR coupling constants are reported in Hertz (Hz) and refer to apparent multiplicities. The assignments of signals were done using 2D homonuclear 1 H-1 H COSY, NOESY and heteronuclear 1 H- 13 C HMQC or HSQC, and HMBC spectra. NMR spectra were processed in Spinworks version 4.1 (developed by Dr. Kirk Marat, Department of Chemistry, University of Manitoba). High-resolution electrospray mass spectra were recorded on a Thermo Scientific Q Exactive Focus Hybrid Quadrupole-Orbitrap mass spectrometer. Ions generated by ESI were detected in negative ion mode. Total ion count (TIC) was recorded in centroid mode over the m/z range of 500-3,000 and analyzed using ThermoXcalibur Qual Browser. Analytical thinlayer chromatography was performed on Kieselgel 60 F254 precoated aluminum plates (Merck). Silica gel column chromatography was performed using silica gel 60 (40-63 µm). Oligonucleotide syntheses were carried out on a MerMade-4 DNA/RNA synthesizer (BioAutomation) or on an Applied Biosystems 394 DNA/RNA synthesizer on a 1-5 µmol scale using standard manufacturer's protocol. 'Saltless buffer' used for oligonucleotide desalting consists of 10 µM Tris-HCl (pH 8.0), 1 µM EDTA and 0.001% w/v NaN3. Scheme S1. Reagents and conditions: i, CHCl3, distill., 10 min, 54%, α/β=12:88 (3a); ii, 28% aq. ammonia, MeOH, 48 h, (3b); iii, 4,4′-dimethoxytritylchloride, pyridine, 0°C→r.t., overnight, 54% (4a); iv, N,N-diisopropylamino-2-cyanoethoxychlorophosphine, Et3N, CH2Cl2, 30 min, 88% (4b). (2) was prepared as previously described. 3 Suspension of 2-hydroxypyrimidine hydrochloride (13.25 g, 100.0 mmol) and catalytic amounts of (NH4)2SO4 in hexamethyldisilazane (37.2 mL, 179.0 mmol) was refluxed for 4h. Reaction mixture was fractionally distilled under reduced pressure to yield 2-trimethylsilyloxypyrimidine (15.33 g, 91%) as cloudy liquid. B.p. (10 mbar) 82-83°C. 1 H NMR (500.1 MHz, CDCl3) δ 8.46 (d, 2H, J = 4.8 Hz, H-4,6), 6.89 (t, 1H, J = 4.8 Hz, H-5), 0.38 (s, 9H, H-CH3). 13 C NMR (125.7 MHz, CDCl3) δ 163.7 (C2), 159.3 (2C, C4), 114.9 (C5), 0.1 (3C, CH3).
Synthetic procedures

2-Trimethylsilyloxypyrimidine
Balloon with Ar
Fresh, dry CHCl 3 Chart S1. Set-up used for the synthesis of 3a.
3',5'-Di-O-(p-toluoyl)-2'-deoxyzebularine (3a)
was prepared by silyl-Hilbert-Johnson reaction with modification described earlier. 4 In a round bottom two-neck flask (Chart S1) was placed dry CHCl3 (6 mL) and distillation started with a speed 2-2.5 mL/min. Fresh chloroform was added through dropping funnel with the same speed to keep the reaction volume (6 mL) constant. 2-Trimethylsilyloxypyrimidine 2 (1.51 g, 9.0 mmol) followed by Hoffer's chlorosugar 1 (1.17 g, 3.0 mmol) were added and distillation was continued for 10 min. keeping reaction volume constant. Solvent was rotary evaporated and residue was flash chromatographed on silica eluting with a step gradient of acetone (0→30%) in CH2Cl2 to yield 3a (0.72 g, 54%) with α/β ratio 12:88 as a colorless foam. This mixture of anomers was used in the next step without isolation of pure β-anomer. Rf 0.58 (α-anomer), 0.51 (β-anomer) (1-BuOH).
5'-O-(4,4'-Dimethoxytrityl)-2'-deoxyzebularine (4a) was prepared similarly to the procedure described earlier. 5 3',5'-Toluoyl protected 2'-deoxynucleoside 3a with α/β ratio 12:88 (6.10 g, 13.6 mmol) was dissolved in MeOH (500 mL) and aq. ammonia (28%, 50 mL) was added in one portion. Reaction mixture was stirred at room temperature for 48 h, rotary evaporated, co-evaporated with H2O (2 × 200 mL), abs. EtOH (200 mL) and abs. pyridine (200 mL) to afford deprotected nucleoside 3b as a yellowish oil. It was dissolved in abs. pyridine (140 mL), cooled to 0°C and 4,4'-dimethoxytritylchloride (5.06 g, 14.9 mmol) was added. Reaction was stirred overnight on a melting ice bath, evaporated in vacuo, residue was dissolved in CH2Cl2 (250 mL), washed with H2O (250 mL), satd. NaHCO3 (250 mL) and brine (250 mL), filtered through Na2SO4 and rotary evaporated in vacuo. Flash chromatography on silica eluting with a step gradient of 2-propanol (0→7%) in a mixture of CH2Cl2/Et3N 99:1 (v/v) afforded pure β-anomer 4a (3.80 g, 54% on 3a) as a yellowish foam after rotary evaporation of solvent. DMTprotected α-anomer eluted after the β-anomer and was not collected. 
5'-O-(4,4'-Dimethoxytrityl)-2'-deoxyzebularine-3'-O-(2-cyanoethyl-N,Ndiisopropylphosphoramidite) (4b)
was prepared similarly to the protocol described earlier. 5 5'-O-DMT-2'-deoxyzebularine 4a (2.70 g, 5.25 mmol) was co-evaporated with abs. CH2Cl2 (100 mL), dissolved in abs. CH2Cl2 (50 mL) and Et3N (1.10 mL, 7.9 mmol) followed by addition of N,N-diisopropylamino-2-cyanoethoxychlorophosphine (1.61 g, 6.8 mmol) under argon. After 30 min stirring reaction was complete (TLC in CH2Cl2/AcOEt/Et3N 45:45:10), reaction mixture was diluted with CH2Cl2 (100 mL), washed with H2O (100 mL), satd. NaHCO3 (3 × 100 mL), filtered through Na2SO4 and rotary evaporated. The residue was purified by flash chromatography on silica (50 mL, packed in CH2Cl2/AcOEt/ Synthesis of oligos 7-9 Oligonucleotides were prepared on a MerMade-4 DNA/RNA synthesizer (BioAutomation) on a 5 µmol scale using standard manufacturer's protocol. Phosphoramidite 4b and commercially available phosphoramidite of 5-methyl-2'-deoxyzebularine were used in the synthesis of modified oligonucleotide sequences ( Table S1 ). Coupling time of 2'-deoxyzebularines was increased to 5 min. The final detritylation step was omitted and DMT-ON oligonucleotides were cleaved from the solid support and deprotected with conc. ammonia solution (1.0 mL) at room temperature for 24 h. After filtering, an aq. solution of 0.3 M LiClO4 (0.5 mL) was added and oligonucleotides were precipitated with acetone (14 mL). The DMT-ON oligonucleotides were isolated by reversed-phase HPLC on 250/10 mm, 5 µm, 300 Å C18 column (Phenomenex) in a gradient of CH3CN (0→60% for 15 min, 4.6 mL/min) in 0.1 M TEAA buffer (pH 7.0) with a detection at 260 nm. DMT-ON oligonucleotides were freezedried and manually detritylated with 80% aq. AcOH (2 mL) during 20 min at room temperature. 3 M AcONa solution (0.5 mL) was then added and oligonucleotides were precipitated with 2-propanol (11 mL). DMT-OFF oligonucleotides were purified by RP-HPLC on 250/4.6 mm, 5 µm, 300 Å C18 column (Phenomenex) in a gradient of CH3CN (0→25% for 20 min, 1.3 mL/min) in 0.1 M TEAA buffer (pH 7.0). Fractions containing desired oligonucleotides were combined, freeze-dried, dissolved in milli-Q water (1.5 mL) and desalted on a NAP-25 column (GE Healthcare) against 'saltless buffer'. Pure products were quantified by measuring absorbance at 260 nm, analyzed by ESI-MS (Table 1 -SI) and concentrated by freeze-drying.
Synthesis of oligo-15
DMT-protected phosphoramidite of dZ synthesized according to the previously published procedure 5, 6 was incorporated into 5'-TTTTdZAT using an Applied Biosystems 394 DNA/RNA synthesizer on 1 μmole scale using a published protocol. 7 The 2'-deoxyzebularine phosphoramidite was incorporated into the oligonucleotide by a manual coupling following deprotection (trityl-off) of the 3'-nucleotide using the technique reported previously by our group. 7 The oligonucleotide was purified by HPLC (Agilent 1200 series instrument equipped with a diode array detector) using PLRP-S column (5 μm, 100 Å, 4.6 × 150 mm, Agilent Technologies). The analysis method (1 mL/min flow rate) involved isocratic 98% Solvent A (100 mM TEAA; pH 7.0) and 2% Solvent B (1:1 of 100 mM TEAA/MeCN) (0−5 min) followed by two linear gradient to 15% Solvent B (5−15 min) and 35% Solvent B (15−50 min) and finally a linear gradient to 80% Solvent B (50−60 min). After purification, the oligonucleotide was desalted with DNase/RNase-free H2O using Illustra NAP-5 columns (Sephadex G-25 DNA grade). The desalted oligonucleotide was characterized by LC-MS (Table 1 -SI) using our previously reported method. 7   Table S1 . TSA-modified Oligos synthesised and purified using protocols described above in 1.2 and 1.3.
Name
Sequence 
Protein expression and purification for ITC and NMR kinetic assays
A3 enzymes and substrate preferences
In this study we focus on human A3A and the catalytically active C-terminal domains of A3B (A3BCTD) and A3G (A3GCTD) (sequences in Fig. S3 ). Wild type hA3A and hA3BCTD expressed in human cells were used in fluorescence-based activity assay. Because wild type A3BCTD (wtA3BCTD) does not express well, when purified from E. coli, we used derivatives of A3BCTD (A3BCTD-DM, A3BCTD-QM-ΔL3, and A3BCTD-QM-∆L3-AL1swap). 8 A3BCTD-QM-∆L3-AL1swap is the most active of all A3BCTD listed mutants; A3BCTD-DM is less active but the sequentially closest to wtA3BCTD. A3BCTD-QM-∆L3-AL1swap, A3BCTD-DM, and A3GCTD were used in NMR-based activity and inhibition assays to test dZ-containing oligos. A3BCTD-QM-ΔL3 has very low activity in our NMR assay, and therefore was used in thermal shift assay together with its inactivated mutant A3BCTD-QM-ΔL3-E255A. 9 Additionally, inactivated A3A-E72A, was used to study A3A binding to ssDNA.
Human A3A-E72A expressed in E. coli
For ITC experiments, human APOBEC3A (1-199, Uniprot code P31941) was cloned as the inactive E72A mutant with a His6 C-terminal fusion tag into an expression vector (pETite, Lucigen) and expressed in Escherichia coli BL21 DE3 cells (Hi-Control, Lucigen). The expression medium was supplemented with 100 μM Zn 2+ . Cells were grown in 5 L shake flasks at 37 °C and shortly before induction cooled to 20 °C. Protein expression was induced with 0.25 mM IPTG and protein was expressed at 20 °C overnight. Cells were harvested and resuspended in the following buffer: 25 mM sodium phosphate, pH 7, 500 mM sodium chloride, 5 mM β-mercaptoethanol and 0.2 mM Na2-EDTA or optimized buffer (25 mM sodium phosphate, 500 mM sodium chloride, 5 mM β-mercaptoethanol and 0.2 mM Na2-EDTA at pH 6.0 plus 300 mM choline acetate and 0.1 mM LysoFos Choline 12 (Anatrace) as described earlier). 10 Cells were disrupted by sonication or French press, with about twice the yields for the latter method. Lysate was cleared by centrifugation (25 min, 4 °C, 38 000 g) and the supernatant was collected. The protein was purified by metal affinity chromatography. After loading the supernatant, a Ni 2+ -NTA affinity column (BioRad) was washed three times with 10 column volumes of one of the above buffers containing 50 mM imidazole followed by one wash with 200 mM imidazole and eluted with 1 M imidazole. The eluted protein was loaded onto a gel filtration column (Highload 16/600 Superdex 75 pg) and the peak shortly before 100 mL elution volume was collected. The protein was concentrated to about 100 µM using Centricons (Vivaspin 20, 10 kDa MWCO) and aliquots were frozen at -70 °C in the optimized buffer.
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Fluorescence polarization assays were performed with recombinant (purified from E. coli strain BL21[DE3]), A3A (amino acids 1-195, expressed using the pGEX vector as a GST-fusion) 9 with the catalytic glutamic acid mutated to alanine (E72A) to render the enzyme unable to deaminate substrate. Before use in the fluorescence polarization assay, protein buffer was exchanged from protein storage buffer to FP assay buffer.
Human A3BCTD-QM-∆L3 and A3BCTD-DM mutants expressed in E. coli
A3B C-terminal domain (residues 187 to 378, UniProt ID Q9UH17) was cloned into pET24a vector (Novagen) to produce A3BCTD proteins with a non-cleavable C-terminal His6-tag (LEHHHHHH). 9 Several derivative constructs previously reported 8 were used in this study, A3BCTD -QM-∆L3, A3BCTD -QM-∆L3-E255A were expressed in E. coli strain BL21(DE3) (Lucigen), and A3BCTD -QM-∆L3-AL1swap expressed in the E. coli strain C41(DE3)pLysS (Lucigen). E. coli culture was grown at 37 °C in LB medium, once mid-log growth phase was established the culture supplemented with 100 µM zinc chloride, before inducing protein expression by the addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) at a final concentration of 0.5 µM and incubating overnight at 18 °C.
The cell culture was harvested via centrifugation and resuspended in 50 mM Tris-HCl (pH 7.4), 0.5 M NaCl, and 5 mM β-mercaptoethanol 50, lysed by sonication and soluble protein was purified through a Ni 2+ -NTA affinity column (BioRad) eluting the protein with 500 mM imidazole. The eluted proteins were loaded through a Superdex 75 10/300 GL column (GE Healthcare) using ÄKTA protein purification system (GE Healthcare) producing a monomeric peak between 90 and 120 mL (see for example Chart S2). The purified proteins were concentrated using Centricons (Vivaspin 20, 10 kDa MWCO) and aliquots were frozen at -80 °C.
A3BCTD -DM was expressed and purified as reported in the recent paper. 8 S11
Human A3GCTD expressed in E. coli
A3GC (191-384, NM_021822, wt) was purified as described. 11 The glutathione Stransferase (GST)-fused A3GCTD was expressed in Escherichia coli BL21(DE3) cells overnight at 17°C. After harvesting, the cells were resuspended in 50 mM sodium phosphate buffer (pH 7.4) and lysed by sonication. After ultracentrifugation at 25,000 g for 10 min, the supernatant was added to glutathione (GSH)-Sepharose, which was subsequently washed. For kinetic analysis, the GST fusion protein was eluted from the Sepharose matrix with 100 mM GSH in phosphate buffer. By using filtration at 4,000 g, the buffer was changed to a solution containing 75 mM sodium phosphate and 75 mM citrate, at pH 5.5.
A3BCTD-QM-∆L3
A280 ( Where 'Lb' = bound tracer concentration, 'Lo' = total tracer concentration, 'Ro' = total protein concentration, 'Lb' = bound tracer concentration using Equations 2 and 3 to calculate these parameters:
We then measured the reliability of the A3A-E72A fluorescence polarization assay by measuring the Z' as recommended for assay validation. 16 Fluorescence polarization assays were performed as described above. Alternating maximum (max), medium (mid), and minimum (min) signal values were distributed by column in a standard interleaved-signal 384 well format. Max signal value wells consisted of A3A-E72A protein (SB80) and fluorescent tracer (15 nM) in assay buffer. Mid signal value wells consisted of protein (SB80), fluorescent tracer (15 nM 
Isothermal titration calorimetry
Desalted unmodified DNA oligonucleotides were purchased (Integrated DNA Technologies) at 1 or 5 µmol synthesis scale and dissolved in one of the buffers described below to give 10 mM solutions.
ITC experiments (Charts S4 -S12) were conducted at 25 °C using a Micro-Cal ITC200 (now Malvern Instruments) isothermal titration calorimeter. A3A-E72A (130 µM in high salt or 33 µM in medium salt buffer) or A3BCTD -QM-∆L3-AL1swap (100 µM, activity assay buffer) was titrated in corresponding buffer. DNA oligonucleotides at 1.6 mM (for A3A-E72A) or 300 µM (for A3BCTD-QM-∆L3-AL1swap) concentration were added in 18 steps at 2.0 µL each (plus a first addition with reduced volume of 0.4 µL to prevent dilution of the DNA in the syringe due to the long wait before the start of the experiment). Oligos and the enzymes were dialyzed against the appropriate buffer. Buffers used are given below:
For A3A-E72A: High salt buffer consists of 25 mM sodium phosphate, 500 mM NaCl, 300 mM choline acetate, 5 mM β-mercaptoethanol and 0.2 mM Na2-EDTA, pH 6.0 or medium salt buffer consists of 50 mM MES, 100 mM NaCl, 2.0 mM tris(2-carboxyethyl)phosphine, pH 6.0.
For A3BCTD -QM-∆L3-AL1swap: Activity assay buffer consists of 50 mM citratephosphate buffer, 200 mM NaCl, 2 mM β-mercaptoethanol, pH 5.5.
Analysis of ITC data was performed with Origin 7 ITC200 software, raw data were fitted to a one-site binding model producing ΔH, ΔS and Ka values (Table S2 ).
S15 ITC data:
Chart S4. Titration of Oligo-1 into A3A-E72A in high salt (left) and medium salt (right) buffers. The upper panel shows the raw injection data, and the lower panel shows the integrated injection enthalpies after background correction. The solid line in the lower panel represents a fit of the data to a one-site binding model.
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Chart S5. Titration of Oligo-2 into A3A-E72A in high salt (left) and medium salt (right) buffers. The upper panel shows raw injection data, and the lower panel shows integrated injection enthalpies after background correction. The solid line in the lower panel represents a fit of the data to a one-site binding model.
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Chart S6. Titration of Oligo-3 into A3A-E72A in a medium salt buffer. The upper panel shows raw injection data, and the lower panel shows integrated injection enthalpies after background correction. The solid line represents a fit of the data to a one-site binding model.
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Chart S7. Titration of Oligo-4 into A3A-E72A in a medium salt buffer. The upper panel shows raw injection data, and the lower panel shows integrated injection enthalpies after background correction. The solid line represents a fit of the data to a one-site binding model.
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Chart S8. Titration of Oligo-5 into A3A-E72A in a medium salt buffer. The upper panel shows raw injection data, and the lower panel shows integrated injection enthalpies after background correction. The solid line represents a fit of the data to a one-site binding model.
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Chart S9. Titration of Oligo-6 into A3A-E72A in a medium salt buffer. The upper panel shows raw injection data, and the lower panel shows integrated injection enthalpies after background correction. The solid line represents a fit of the data to a one-site binding model.
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Chart S10. Titration of Oligo-7 into A3A-E72A in a medium salt buffer. The upper panel shows raw injection data, and the lower panel shows integrated injection enthalpies after background correction. The solid line represents a fit of the data to a one-site binding model.
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Chart S11. Titration of Oligo-8 into A3A-E72A in a medium salt buffer. The upper panel shows raw injection data, and the lower panel shows integrated injection enthalpies after background correction. The solid line represents a fit of the data to a one-site binding model.
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Chart S12. Titration of Oligo-9 into A3BCTD -QM-∆L3-AL1swap in the activity assay buffer. The upper panel shows raw injection data, and the lower panel shows integrated injection enthalpies after background correction. The solid line in the lower panel represents a fit of the data to a one-site binding model. ATTCCdZAATT dZ-modified oligos for direct comparison to substrate (Oligo-3) above and to study A3GCTD inhibition Oligo- 8 ATTCCdZ
Me
AATT
Oligo-9
ATTTdZATTT dZ-modified oligo to study A3BCTD inhibition Oligo- 15 TTTTdZAT
Modified oligo for direct comparison to substrate (Oligo 10) above in FP assay Oligo- 16 5'-(6-FAM)TTT TCAT Fluorescent DNA tracer for FP assays S26
Thermal Shift Assay
A fluorescence-based thermal shift assay was used to assess binding capability of ssDNA oligonucleotides to A3BCTD proteins, through examination of changes in the proteins thermal stability. Binding assays were conducted using inactive A3BCTD protein constructs, A3BCTD-QM-ΔL3 and A3BCTD-QM-ΔL3 (E255A), where dC substrate is not converted to dU, and to determine if differences in binding occur due to a single amino acid change (E255A) in the protein.
Purified A3BCTD protein was appropriately diluted in optimised NMR buffer (50 mM citrate-phosphate pH 5.5, 200 mM NaCl, 2 mM β-mercaptoethanol, pH 5.5, 200 µM 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS)). Assay experiments were setup in a total volume of 25 µl containing; 20 µM A3BCTD protein, 100 µM ssDNA oligonucleotide, mixed with SYPRO® orange dye (BioRad) at a final concentration of 10X. Assays were dispensed into wells of a white Low-Profile 96-Well plate (Roche) then sealed with optical seal, shaken, and centrifuged. Thermal scanning (20 to 95°C at 0.6°C/min) was performed using a real-time PCR setup on a LightCycler 480 instrument II (Roche) with fluorescence emission spectra recorded with combinations of excitation and emission filters (483-610 and 483-568 nm, respectively).
Chart S13. Thermal denaturation profiles obtained for A3BCTD-QM-ΔL3 (E255A, left) and A3BCTD-QM-ΔL3 (right) in the absence (buffer) and in the presence of oligos. The melting temperatures for A3BCTD-QM-ΔL3-E255A and A3BCTD-QM-ΔL3 in absence of oligo(buffer) are 49.00 ± 0.04 and 54.75 ± 0.33, respectively.
Raw fluorescent intensity data was normalised to percentage, fit to curves, then melting temperature calculation (Tm) was determined at the midpoint (50 %), defined when a protein's melting transition occurs between the folded and unfolded states. Assessment 
A3BCTD-QM-ΔL3
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of binding of the ssDNA oligonucleotides to the A3BCTD proteins were measured by examining the change in melting temperature (ΔTm) in the presence of oligo compared to absence (buffer) of oligo. Experimental replicates were performed which were analysed using a Q-test for the identification and rejection of outliers based on a 95% confidence interval. Cleavage of oligonucleotides containing an abasic site using NaOH (4 M, 3 µL) occurred after 30 min reaction incubation at 37 °C. Plates were read using BioTek Synergy H1 plate reader with an excitation wavelength at 490 nm and emission at 520 nm. Each experiment was performed in biological duplicate with three technical replicates per condition. Resulting total fluorescence values were reported together with the no-protein low control and protein only high control (no inhibitors). nonspecific inhibitor MN-1 was used as a positive control (Fig. S1 ).
Kinetic characterisation of A3BCTD-QM-∆L3-AL1swap and A3BCTD -DM
The kinetic characterization of A3BCTD -QM-∆L3-AL1swap and of A3BCTD -DM on dATTTCATTT substrate was conducted using an established one-dimensional proton-NMR (1D 1 H-NMR) based assay. 11 This assay utilizes the naturally abundant proton ( 1 H) isotope nuclei within ssDNA molecule and monitors the real-time deamination of the dC (substrate, dATTTCATTT) to dU (product, dATTTUATTT). Measurements were acquired on a 700-MHz Bruker NMR spectrometer equipped with a 1.7-mm cryoprobe at 298 K. A series of 1 H NMR spectra was recorded of the oligonucleotide substrate 5'-dATTTCATTT at concentrations ranging from 50 µM to 750 µM with 50 nM of A3BCTD -QM-∆L3-AL1swap protein or 2 µM of A3BCTD -DM in a buffer (50 mM citrate-phosphate, 200 mM NaCl, 2 mM β-mercaptoethanol, 200 µM 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS); pH 5.5 for A3BCTD -QM-∆L3-AL1swap, pH 7.5 for A3BCTD -DM) containing 10 % deuterium oxide. The H-5 proton doublet signal of the cytosine, which appears between 5.92 to 5.88 ppm, was baselined and integrated (Chart S14, example for A3BCTD -QM-∆L3-AL1swap). A doublet of doublets at 2.57 to 2.39 ppm originating from citrate buffer was used as an internal standard to determine the concentration of substrate converted during the reaction. The integrated signal area was converted to substrate concentration and plotted versus time of the reaction. This plot was then fitted with linear regression to determine the initial speed of the reaction. Charts S15 and S17 show the dependence of speed of the reaction on substrate concentration for A3BCTD -QM-∆L3-AL1swap and A3BCTD -DM, respectively. The double reciprocal plots (Charts S16 and S18) were then fitted with linear regression to determine Km, and kcat using the following formula (showing numbers obtained for A3BCTD -QM-∆L3-AL1swap with enzyme concertation [E] = 50 nM): Uncertainties of Km and kcat were calculated from regression fit (Chart S16 ) using LINEST function of Excel.
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Activity data for A3BCTD -QM-∆L3-AL1swap:
Chart S14. 1 H-NMR spectra for the substrate (dAT3CAT3) and its conversion to the product (dAT3UAT3) over time in the presence of A3BCTD -QM-∆L3-AL1swap (50 nM) at 298 K in activity assay buffer.
Chart S15. Speed of deamination catalysed by A3BCTD -QM-∆L3-AL1swap (50 nM) as a function of substrate (dAT3CAT3) concentration. 
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Chart S16. Double reciprocal plot of inversed speed of deamination catalysed by A3BCTD -QM-∆L3-AL1swap (50 nM) as a function of the inversed substrate concentration (dAT3CAT3).
Activity data for A3BCTD -DM:
Chart S17. Speed of deamination catalysed by A3BCTD -DM as a function of substrate (dAT3CAT3) concentration. 
S32
Chart S18. Double reciprocal plot of inversed speed of deamination catalysed by A3BCTD -DM as a function of the inversed substrate concentration (dAT3CAT3). 
Calculation of inhibition of A3BCTD -QM-∆L3-AL1swap and A3BCTD-DM
by Oligo-9 Based on activity assay described above, measurements of the inhibition of A3BCTD -QM-∆L3-AL1swap and of A3BCTD -DM deaminase activity by dZ-containing oligonucleotide were conducted. A series of 1 H NMR spectra was recorded of the substrate 5'-ATTTCATTT at constant concentration of 350 µM with varying concentrations of the inhibitor 5'-ATTTdZATTT ranging from 5 µM to 100 µM in the presence of 50 nM of A3BCTD-QM-∆L3-AL1swap or of 2 µM of A3BCTD-DM in activity assay buffer as mentioned previously at 298 K. Integration of the H-5 proton doublet signal of the cytosine (between 5.92 to 5.88 ppm) which was then converted to substrate concentration and plotted versus time of the reaction. This plot was then fitted with linear regression to determine the speed of the reaction in the presence of inhibitor. The plot of inverse speed versus inhibitor concentration was then fitted with linear regression to derive the inhibition constant (Ki) using the following formula and Km and kcat values obtained above for A3BCTD -QM-∆L3-AL1swap (numbers shown) and for A3BCTD -DM. Uncertainty of Ki was calculated using error-propagation method. E--------SGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN A3BCTDQM∆L3E255A E--------SGRHAALRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN **** * ***..* ** * **** * ******* ** * *. * A3GCTD KHVSLCIFTARIYDD-QGRCQEGLRTLAEAGAKISIMTYSEFKHCWDTFVDHQGCPFQPW hA3A THVRLRIFAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQPW  A3A-E72A  THVRLRIFAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFKHCWDTFVDHQGCPFQPW  hA3BCTD  THVRLRIFAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPW  A3BCTDDM  THVRLRIKAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPW  A3BCTDQM∆L3  THVRLRIKAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPW  A3BCTDQM∆L3AL1 THVRLRIKAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPW A3BCTDQM∆L3E255A THVRLRIKAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPW ** * * ***** *.* * *** .***** ** .****** ******** A3GCTD  DGLDEHSQDLSGRLRAILQNQEN  hA3A  DGLDEHSQALSGRLRAILQNQGN  A3A-E72A  DGLDEHSQALSGRLRAILQNQGN  hA3BCTD  DGLEEHSQALSGRLRAILQNQGN  A3BCTDDM  DGLEEHSQALSGRLRAILQ----A3BCTDQM∆L3  DGLEEHSQALSGRLRAILQ----A3BCTDQM∆L3AL1 DGLEEHSQALSGRLRAILQ----A3BCTDQM∆L3E255A DGLEEHSQALSGRLRAILQ----******** ********** Figure S4 . Deamination of dC in 1mM 5'-dAATTCAAAA by the 100 µM of A3Bctd-QMΔL3 protein over time.
